Biodesix Approves Reverse Stock Split at Annual Meeting

Biodesix ( (BDSX) ) just unveiled an update.

Biodesix, Inc. held its 2025 annual meeting of stockholders on May 20, 2025, where several key decisions were made. The stockholders elected two Class II directors, ratified KPMG LLP as the independent registered public accounting firm, approved a reverse stock split of the company’s common stock, and amended the Employee Stock Purchase Plan to increase available shares.

The most recent analyst rating on (BDSX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Biodesix stock, see the BDSX Stock Forecast page.

Spark’s Take on BDSX Stock

According to Spark, TipRanks’ AI Analyst, BDSX is a Neutral.

Biodesix’s overall stock score is impacted by significant financial instability and weak technical indicators. While the company shows strong revenue growth and operational efficiencies, high leverage and poor profitability are major concerns. The earnings call provided some optimism with positive developments, but challenges in sales force reconfiguration and market expansion remain. Valuation is unattractive due to negative earnings and lack of dividends.

To see Spark’s full report on BDSX stock, click here.

More about Biodesix

Average Trading Volume: 2,337,188

Technical Sentiment Signal: Sell

Current Market Cap: $44.12M

Find detailed analytics on BDSX stock on TipRanks’ Stock Analysis page.